Instalab
logoInstalab

Enterobacter Ludwigii

Stool Test
Find out whether a hospital-associated, drug-resistant gut bug is quietly colonizing your microbiome.
4.9 (3,998 reviews)
Physician-reviewed results
Results in under 1 week
How it works
Order from Instalab
No prescription or your own doctor's order needed
Collect your sample
At home
Get results
Explained with clear next steps, no medical jargon

Should you take a Enterobacter Ludwigii test?

This test is most useful if any of these apply to you.

Recently in the Hospital
If you have had an admission, surgery, or extended IV therapy, you can carry hospital-acquired gut bacteria home without symptoms.
Taking Acid Blockers Long-Term
Daily proton pump inhibitor use raises the odds your gut harbors drug-resistant bacteria from this family.
Living With Recurrent Gut Symptoms
If your digestion has been off for months, this organism can be one piece of a larger microbial imbalance worth mapping.
Mapping Your Microbiome
If you are building a baseline picture of your gut bacteria, this species is part of the opportunist population worth tracking.

About Enterobacter Ludwigii

Most people never hear about this organism until it shows up on a stool report or a hospital culture. That is part of the problem. It can sit quietly in your gut for weeks without symptoms, then turn into a serious infection if you end up in a hospital bed, on antibiotics, or with a catheter or central line in place.

Knowing whether you carry it now, while you feel fine, gives you a baseline. If you later need surgery, an antibiotic course, or hospital care, both you and your clinicians can factor that information in. This is a research-grade microbiome marker without standardized clinical cutpoints, so think of it as one signal among many rather than a stand-alone verdict.

What This Bacterium Is

Enterobacter ludwigii (E. ludwigii) is a single species inside a tightly related group called the Enterobacter cloacae complex (a cluster of closely related gut bacteria that often act as opportunistic invaders in vulnerable people). On standard stool panels, it is reported as part of your overall microbial picture. It is not a hormone, a protein, or a metabolite. It is a living organism that either is or is not present in your gut at detectable levels.

In a healthy gut, Enterobacter species typically sit in the background. They become a problem when they overgrow, acquire resistance genes, or get the chance to spread to places they should not be, like the bloodstream or the surface of an indwelling medical device.

Why It Shows Up in Hospital Outbreaks

In a 1,400-bed Israeli hospital, 34 patients across 24 wards were found to be carrying E. ludwigii during a four-month outbreak. Most were detected through rectal swabs and had no infection at all. Many came in from home with relatively few invasive devices and no prior history of multidrug-resistant carriage, which suggested a community source that then spread inside the hospital. Genetic analysis showed the strains were almost identical, with fewer than 20 single-letter DNA differences, consistent with rapid spread from a single origin.

The takeaway for you: silent gut carriage is the rule, not the exception. People can carry this organism without knowing it and still pose a transmission risk in healthcare settings, or be at risk themselves if their immune defenses drop.

Antibiotic Resistance Concerns

All 34 isolates from the Israeli outbreak carried a gene called blaIMI-17, which produces an enzyme that disables carbapenems, one of the strongest classes of antibiotics. The strains were resistant to ceftriaxone, piperacillin-tazobactam, ertapenem, and meropenem, while still being susceptible to ceftazidime, fluoroquinolones, aminoglycosides, nitrofurantoin, and trimethoprim-sulfamethoxazole. Not every E. ludwigii strain is this resistant. A separate ICU bloodstream infection case involved a strain that responded well to standard antibiotics.

What this means for you: if a stool test flags E. ludwigii, the species name alone does not tell you whether the strain is drug-resistant. That requires a culture with susceptibility testing, which is the standard follow-up if the organism ever causes a clinical infection.

Why Biofilms Matter

In a published case, a 57-year-old patient in intensive care developed a bloodstream infection traced back to E. ludwigii growing in a thick, slimy coating (called a biofilm) on the outside of their central venous catheter (a long IV line that goes into a large vein near the heart). Biofilms shield bacteria from antibiotics and from the immune system, which is part of why E. ludwigii is hard to clear once it has set up shop on a device. If you are headed for any procedure involving a long-term catheter, this background risk is worth knowing about.

Reference Ranges

There are no published human reference ranges, risk-stratification tiers, or guideline cutpoints for E. ludwigii in stool. Most stool panels report it as detected or not detected, sometimes with a relative abundance figure. For comparison, in kidney transplant recipients, a 1% relative gut abundance of Escherichia or Enterococcus on 16S rRNA sequencing (a DNA-based method for identifying gut microbes) was an independent risk factor for urinary tract infections caused by those organisms. No equivalent threshold exists for Enterobacter or E. ludwigii. The most useful approach is to compare your own results across time, in the same lab, using the same assay.

Tracking Your Trend

Gut bacteria fluctuate with diet, antibiotic use, illness, and travel, so a single result is a snapshot, not a verdict. Tracking how E. ludwigii changes over time is more informative than any one reading. If a baseline test detects the organism, a repeat at three to six months, especially after any antibiotic course or hospital stay, will tell you whether it is sticking around or has cleared.

Because labs differ in how they detect and quantify Enterobacter species, stay with the same provider and the same method for serial comparisons. Comparing a culture-based result from one lab to a DNA-based result from another can produce confusion that has nothing to do with what is happening in your gut.

What an Abnormal Result Should Make You Do

Detection on a stool panel in someone with no symptoms usually means colonization, not infection. The action steps depend on the rest of the picture. If you have ongoing digestive symptoms, pair the result with markers of gut inflammation like calprotectin (a protein released by inflamed gut cells) and pancreatic elastase (an enzyme that reflects how well your pancreas is digesting food). If you are heading into surgery or a long hospital admission, share the result with your care team so they can factor it into their infection-prevention plan. If you have a recurrent infection that grows E. ludwigii on culture, ask for full antibiotic susceptibility testing and consider involving an infectious disease specialist, especially if the strain produces a carbapenemase enzyme.

When Results Can Be Misleading

  • Recent antibiotics: any course in the prior weeks can suppress or unmask Enterobacter species, so a single reading after antibiotic exposure may not reflect your usual gut composition.
  • Acute illness or travel: infections, food poisoning, and travel-related diarrhea reshape the gut microbiome temporarily and can shift Enterobacter detection up or down.
  • Sample handling: stool that sits at room temperature too long, or that is collected without the kit's preservative, can change which organisms are recovered.
  • Lab method differences: culture, 16S rRNA sequencing, and shotgun metagenomics (a DNA method that reads all microbial genes in a sample) detect E. ludwigii at different sensitivities, so switching labs mid-track can create artificial swings.

What Moves This Biomarker

Evidence-backed interventions that affect your Enterobacter Ludwigii level

↑ Increase
Take clarithromycin (a macrolide antibiotic)
This antibiotic flips the balance of gut bacteria in a way that lets Enterobacter and related species overgrow. A systematic review of antibiotics commonly prescribed in UK primary care found clarithromycin reduced Escherichia coli while triggering overgrowth of Klebsiella, Citrobacter, and Enterobacter species, with changes lasting up to about five weeks. The review tracked the Enterobacter genus, not E. ludwigii specifically.
MedicationStrong Evidence
↑ Increase
Take a proton pump inhibitor (an acid-blocking drug like omeprazole or pantoprazole)
Acid-blocking drugs raise the chance that your gut becomes home to drug-resistant Enterobacter family bacteria, the same group E. ludwigii belongs to. In a hospital cohort of 4,478 adults, proton pump inhibitor use was linked to about 50% higher odds of acquiring extended-spectrum beta-lactamase or carbapenemase-producing Enterobacterales (gut bacteria carrying genes that disable common antibiotics). The study tracked the broader Enterobacterales group, not E. ludwigii specifically, but E. ludwigii sits inside that group.
MedicationModerate Evidence
↑ Increase
Take long-term NSAIDs (anti-inflammatory drugs like ibuprofen or naproxen) alongside a proton pump inhibitor
Chronic use of these two drugs together disturbs the small intestinal microbiome and is considered an independent risk factor for what doctors call NSAID-associated enteropathy (gut wall damage from anti-inflammatory drugs). The result can favor opportunistic Enterobacterales, the family E. ludwigii belongs to. The reviewed evidence describes the family-level effect, not E. ludwigii specifically.
MedicationModerate Evidence
↑ Increase
Take metformin (a first-line diabetes drug)
Metformin shifts the gut toward more Proteobacteria, the larger bacterial group that includes E. ludwigii. In a randomized trial of 373 adults, metformin treatment increased Proteobacteria such as Escherichia coli. The trial measured the broader group, not E. ludwigii directly, so whether your specific E. ludwigii reading moves on metformin has not been confirmed. Because metformin's overall metabolic and cognitive benefits are well documented, the lab shift alone should not change your treatment decision.
MedicationModest Evidence

Frequently Asked Questions

References

8 studies
  1. Schechner V, Levytskyi K, Shalom O, Yalek a, Adler aAntimicrobial Resistance and Infection Control2021
  2. Magruder M, Sholi a, Gong C, Zhang LT, Lee JRNature Communications2019
  3. Willems RPJ, Schut MC, Kaiser AM, Groot TH, Abu-hanna a, Twisk JWR, Van Dijk K, Vandenbroucke-grauls CMJEJAMA Network Open2023